GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (LTS:0R2M) » Definitions » Repurchase of Stock

Regeneron Pharmaceuticals (LTS:0R2M) Repurchase of Stock : $-4,043 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Regeneron Pharmaceuticals Repurchase of Stock?

Regeneron Pharmaceuticals's Repurchase of Stock for the three months ended in Mar. 2025 was $-1,046 Mil.

Regeneron Pharmaceuticals's Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2025 was $-4,043 Mil.


Regeneron Pharmaceuticals Repurchase of Stock Historical Data

The historical data trend for Regeneron Pharmaceuticals's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Repurchase of Stock Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,527.60 -2,678.10 -2,528.50 -2,935.60 -3,632.40

Regeneron Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -635.00 -915.70 -855.30 -1,226.40 -1,045.70

Regeneron Pharmaceuticals Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4,043 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines